Welcome to our dedicated page for 22Nd Century news (Ticker: XXII), a resource for investors and traders seeking the latest updates and insights on 22Nd Century stock.
22nd Century Group (NASDAQ: XXII) pioneers plant-based solutions for tobacco harm reduction through advanced biotechnology. This news hub provides investors and stakeholders with essential updates on regulatory milestones, product innovations, and operational developments central to the company's mission of reducing nicotine addiction.
Access authoritative coverage of FDA communications, VLN product advancements, and manufacturing capacity updates. Our curated collection includes earnings reports, patent filings, and scientific research collaborations that demonstrate 22nd Century's leadership in developing reduced-nicotine tobacco products.
Key updates feature the company's Modified Risk Tobacco Product authorization, progress in international market expansion, and innovations in nicotine biosynthesis control. Regular updates ensure informed tracking of this biotechnology firm's unique position at the intersection of public health and commercial tobacco production.
Bookmark this page for streamlined access to verified corporate announcements and analysis-free reporting on 22nd Century's progress in redefining tobacco consumption through science-driven solutions.
22nd Century Group (Nasdaq: XXII) will participate in one-on-one meetings at the 35th Annual Roth Conference from March 12-14, 2023, in Orange County, California. This leading biotechnology company focuses on reduced nicotine tobacco and advanced plant technologies. Investors interested in meetings can contact their Roth representative or reach out to Matt Kreps at mkreps@xxiicentury.com.
22nd Century has pioneered proprietary reduced nicotine content tobacco and received the first FDA MRTP authorization for a combustible cigarette in December 2021, emphasizing its commitment to tobacco harm reduction.
22nd Century Group, Inc. (Nasdaq: XXII) announced it will host a live webcast on March 9, 2023, at 10:00 AM ET to discuss its 2022 fourth quarter and full year results, which will be released earlier that day at 6:00 AM ET. CEO James A. Mish and other executives will review the company's financial performance and advancements in its three business franchises. The event will include a Q&A session for research analysts. Investors can access the live and archived webcast on the company's Investor Relations website.
22nd Century Group has announced a significant seed cultivation initiative aimed at producing reduced nicotine content tobacco to meet New Zealand's new tobacco regulations. The project targets the production of up to 2 billion cigarettes, matching the country's annual consumption. The company's VLN® cigarettes, which contain 95% less nicotine than standard options, are set to become a foundational element of public health policies in New Zealand and beyond. The initiative aligns with the government’s Smokefree Aotearoa 2025 plan, positioning 22nd Century as a key player in the global tobacco harm reduction effort.
22nd Century Group, Inc. has launched VLN® cigarettes in Colorado, designed for adults aiming to reduce their nicotine intake. A recent survey reveals that 74% of Colorado smokers wish to quit, with 87% believing that cutting back is vital. VLN® contains 95% less nicotine than traditional cigarettes and has received FDA’s Modified Risk Tobacco Product designation. This initiative aligns with the FDA's regulatory focus on nicotine reduction and could cater to the demand for less addictive tobacco products. The survey indicates potential market interest, particularly since Colorado has reduced taxes on such products.
22nd Century Group has announced the acquisition of RX Pharmatech Ltd, enhancing its foothold in the U.K. and EU cannabinoid markets. The deal includes a $650,000 upfront payment and a three-year equity earn-out based on revenue milestones. This acquisition positions 22nd Century as a leader in the U.K. consumer products isolate market, projected to reach $1.26 billion by 2025. RXP's 1,276 approved novel food applications streamline entry into these markets, aligning with regulatory trends. The integration is expected to improve revenue and gross margins through operational efficiencies.
22nd Century Group, Inc. (XXII) has filed a U.S. Drug Master File (DMF) for pharmaceutical-grade cannabidiol (CBD) active pharmaceutical ingredients (API) with the FDA. This filing underscores the company's commitment to providing high-quality CBD ingredients to pharmaceutical and over-the-counter markets. CEO James A. Mish emphasized the importance of this move in meeting regulatory demands. In addition, 22nd Century has partnered with Cannabinoid API Solutions and Transo-Pharm for global marketing and distribution, tapping into a $1 billion cannabinoid pharmaceutical market.
22nd Century Group has opened a new distribution facility in the Netherlands to enhance access to its hemp/cannabis products in Europe, the Middle East, and Africa.
This facility aims to optimize transaction flow and improve tax and customs treatment, as well as reduce delivery time to partners.
The company is increasing manufacturing capacity in the U.S. to meet growing European demand, projected to reach €3.2 billion by 2025. CEO James A. Mish emphasized the facility's potential to capture more market share and scale operations in a rapidly expanding industry.
22nd Century Group (Nasdaq: XXII) announced its participation as an exhibitor at MJBizCon in Las Vegas from November 16 to 18, 2022. The company aims to showcase its advancements in reduced nicotine tobacco and plant technologies through its GVB Biopharma subsidiary. CEO James A. Mish expressed excitement about the opportunity to demonstrate their expertise in cannabinoid extracts and contract manufacturing. GVB Biopharma is recognized as a leading supplier of cannabinoid extracts in North America with a significant market share.
22nd Century Group, Inc. (Nasdaq: XXII), an agricultural biotechnology firm, has announced its participation in upcoming investor conferences. The events will include one-on-one meetings at the Roth 2nd Annual AgTech Answers Event on November 15, 2022, and the 13th Annual Craig-Hallum Alpha Select Conference on November 17, 2022. Investors interested in meeting with management should contact Roth and Craig-Hallum representatives to arrange meetings. 22nd Century focuses on tobacco harm reduction and innovative plant technologies.
22nd Century Group, Inc. (Nasdaq: XXII) reported third quarter 2022 net sales of $19.4 million, a 148% increase from the same period in 2021. This growth is attributed to increased contract manufacturing volumes and revenues from the recently acquired GVB Biopharma. The company is expanding its reduced nicotine tobacco product, VLN®, into five states, with plans to reach 18 states within a year. Despite a net loss of $13.1 million, the company maintains a strong balance sheet with $43.7 million in cash, supporting strategic initiatives for expansion.
FAQ
What is the current stock price of 22Nd Century (XXII)?
What is the market cap of 22Nd Century (XXII)?
